Q1 EPS Estimate for Arcus Biosciences Lowered by Analyst

Arcus Biosciences, Inc. (NYSE:RCUS) – Stock analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of Arcus Biosciences in a research report issued to clients and investors on Wednesday, February 26th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings of ($1.13) per share for the quarter, down from their prior estimate of ($0.89). The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Leerink Partnrs also issued estimates for Arcus Biosciences’ Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.09) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.41) EPS, FY2026 earnings at ($2.76) EPS, FY2027 earnings at ($1.72) EPS and FY2028 earnings at $1.06 EPS.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm had revenue of $36.00 million for the quarter, compared to the consensus estimate of $29.38 million.

Other research analysts have also recently issued research reports about the stock. Morgan Stanley dropped their price target on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Bank of America lowered their target price on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 19th. Wedbush restated an “outperform” rating and issued a $36.00 price target on shares of Arcus Biosciences in a research report on Thursday, November 7th. Finally, HC Wainwright raised Arcus Biosciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $18.00 to $24.00 in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Arcus Biosciences presently has a consensus rating of “Buy” and a consensus target price of $30.25.

Arcus Biosciences Stock Performance

Shares of NYSE RCUS opened at $9.87 on Friday. Arcus Biosciences has a 12-month low of $9.85 and a 12-month high of $20.10. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -3.13 and a beta of 0.84. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm has a 50 day moving average of $13.46 and a 200 day moving average of $15.42.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the transaction, the chief financial officer now owns 60,138 shares in the company, valued at $902,070. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Terry J. Rosen acquired 19,800 shares of the firm’s stock in a transaction dated Thursday, February 27th. The shares were purchased at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This represents a 0.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

Institutional Trading of Arcus Biosciences

A number of large investors have recently made changes to their positions in the business. R Squared Ltd bought a new position in shares of Arcus Biosciences in the 4th quarter valued at about $26,000. Point72 Hong Kong Ltd purchased a new stake in Arcus Biosciences during the third quarter valued at approximately $47,000. Lazard Asset Management LLC lifted its stake in shares of Arcus Biosciences by 3,321.3% in the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock valued at $93,000 after purchasing an additional 6,078 shares during the last quarter. US Bancorp DE boosted its holdings in shares of Arcus Biosciences by 2,432.0% in the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock worth $103,000 after purchasing an additional 6,615 shares during the period. Finally, Quest Partners LLC increased its position in shares of Arcus Biosciences by 40,904.3% during the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after purchasing an additional 9,408 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.